Objectives: To estimate the number of patients with recurrent respiratory papillomatosis currently managed in secondary and tertiary health care in the UK and the frequency of its treatment with radiofrequency cold ablation (Coblation   TM   ) . Design: Cross-sectional survey of ENT consultants in the UK with validation using Hospital Episode Statistics (HES) inpatient data. Setting: Online survey. Participants: ENT consultants in the UK. Main outcome measures: Number of recurrent respiratory papillomatosis patients currently managed in acute care in the UK and frequency of use of Coblation. Results: A total of 283 ENT consultants from 128 UK NHS healthcare trusts and health boards completed the online survey. Responses were received from 86% of surveyed organisations, and an estimated 45% of all ENT consultants in UK. The estimated number of recurrent respiratory papillomatosis patients from the cross-sectional survey was 918 (at August 2015) which included 730 patients in England. The number of recurrent respiratory papillomatosis patients in England estimated from Hospital Episode Statistics (2014/15 financial year) was up to 741. A total of 42 Coblation procedures conducted in the UK were identified from the crosssectional survey; 36 were conducted in England compared with 34 identified from Hospital Episode Statistics. Conclusions: The numbers of recurrent respiratory papillomatosis patients and Coblation procedures identified in England from a cross-sectional survey and Hospital Episode Statistics were in broad agreement. Our study estimated 1.42 recurrent respiratory papillomatosis patients per 100 000 in the general UK population. We also estimated that Coblation procedures accounted for 3% of interventional treatments conducted in the UK recurrent respiratory papillomatosis population.
Recurrent respiratory papillomatosis is a relatively rare condition, but has a significant impact on patients and their families as it requires repeated anaesthetic procedures to achieve symptomatic control. 1 The most basic estimates of cost for recurrent respiratory papillomatosis suggest that even though it is a rare condition, the cost of care is relatively high.
2 It has been difficult to identify the prevalence for recurrent respiratory papillomatosis as there is no specific diagnosis code 3 or established registry. Previously, a questionnaire of members' experience was sent to the British Association of Paediatric Otolaryngologists to identify treatment trends. 4 That study had limited scope (recurrent respiratory papillomatosis affects both children and adults) and limited coverage (41 respondents, 39% response rate, 27 departments, 103 patients) and did not aim to estimate prevalence.
In 2012, the UK National Institute for Health and Care Excellence (NICE) published Interventional Procedures Guidance on Radiofrequency cold ablation for respiratory papillomatosis. 5 This guidance highlighted a lack of safety and efficacy evidence to support its use in the treatment of recurrent respiratory papillomatosis and recommended that Coblation procedures be conducted with special arrangements for clinical governance, consent and audit or research.
The primary aim of this study was to estimate the total number of children and adults with recurrent respiratory papillomatosis who are currently managed in the UK to provide a baseline for further epidemiological study. A secondary aim was to inform interventional procedure guidance development, in particular the extent to which radiofrequency cold ablation (Coblation TM , Smith and Nephew plc, Huntingdon, UK) was being used as a treatment 
Materials and methods

Ethical considerations
Only aggregated totals of patients and procedures from a 12-month period were collected in the national survey and analysis of Hospital Episode Statistics. No patient identifiable information was used, and no ethical approvals were sought.
National recurrent respiratory papillomatosis surveyStudy participants A structured online questionnaire was developed in SurveyMonkey (SurveyMonkey Inc., Palo Alto, CA, USA) (Fig. 1) Estimated UK prevalence and management of RRP 87 devolved administrations to encourage completeness. ENT UK also supported the survey by distributing (via email) the details of the survey to every ENT UK member (including honorary members) and sent a reminder 1 week before the survey closing date.
National recurrent respiratory papillomatosis surveyStatistical analysis
Responses were collated in SurveyMonkey and exported in a Microsoft Excel file. ENT UK provided the total number of ENT consultant members in each home nation, from which the consultant completion rate was estimated. Summary statistics were calculated for all responses; those expressed as 'more than n' were treated as n + 1. When calculating the proportion of recurrent respiratory papillomatosis patients (response to Question 3, Fig. 1 ) who had received at least one interventional procedure (Question 4), values exceeding 100% were considered as typographical errors and interpreted as 100%. Reported use of other interventions (Question 7) without a frequency for their use in the last 12 months (Question 6) was interpreted as historic interventions conducted prior to August 2014. All data analyses were conducted using the statistical programming language R. 6 Hospital Episode Statistics analysis -Data sources and study population A retrospective cohort study was conducted using data from the 2014/15 inpatient data set from Hospital Episode Statistics. 7 An estimate of the number of episodes of care concerning recurrent respiratory papillomatosis was considered as the number of episodes containing at least one of the International Classification of Diseases 10th revision (ICD-10) diagnosis codes defined in Table 1 , appearing in any of the 20 diagnosis fields.
The number of patients was deduced from the number of unique pseudoanonymised patient identifiers (Hospital Episode Statistics field PSEUDO_HESID) in episodes of care for recurrent respiratory papillomatosis. ICD10 codes D10/D14 can also be used to indicate other non-recurrent respiratory papillomatosis diagnoses (e.g. polyps in the airway). Because recurrent respiratory papillomatosis is recurrent, for the purposes of this study, the number of patients with recurrent respiratory papillomatosis was defined as those patients having more than one admission with the specified ICD10 codes during the period of interest. The number of Coblation treatments conducted in this population was considered as the number of admissions containing the Office of Population Censuses and Surveys Classification of Interventions and Procedures (OPCS-4) supplementary code for method of approach 'Y10.1 -Coblation' appearing in any of the 24 procedure fields.
Results
Of the 182 individual organisations contacted with details of the national recurrent respiratory papillomatosis survey, a total of 157 responded; 128 completed the survey and a further 29 indicated the survey was not applicable to their organisation. A total of 289 responses from individual ENT consultants were received from the online survey. Six of these responses were excluded from further analysis because the respondent did not practice in the UK. The numbers of organisations responding from each Home Nation, with estimates of completeness, are shown in Table 2 . The numbers of individual ENT consultants responding from each Home Nation, and estimates of completeness (using ENT UK reported consultant members per Home Nation as the denominator), are also shown in Table 2 .
The total number of recurrent respiratory papillomatosis patients identified from the survey responses was 918, reported by 150 ENT consultants (with the remaining 133 ENT consultants reporting no recurrent respiratory papillomatosis patients currently under their own care). A total of 730 (79.5%) of these patients were reported from ENT consultants in England, 126 (13.7%) from Scotland, 53 (5.8%) from Wales and 9 (1.0%) from Northern Ireland. Based on a population size of 64.6 million, 8 the lower estimate of recurrent respiratory papillomatosis in the UK is 1.42 per 100 000. The 918 patients mentioned in the responses were assumed to be unique individuals.
From ENT consultants reporting recurrent respiratory papillomatosis patients currently under their care, the median [lower quartile (Q1), upper quartile (Q3)] number of recurrent respiratory papillomatosis patients per consultant was 3.5 (2,6) with range 1-69. Of the 918 recurrent respiratory papillomatosis patients reported to be managed One hundred and twenty-five ENT consultants conducted a median (Q1,Q3) of 4 (2,8) with range 1-30 interventional procedures in recurrent respiratory papillomatosis patients within the last 12 months. The proportions using each type of intervention and the total number of times they were used are described in Table 3 .
Of the 42 Coblation procedures, 36 were conducted in England (by 12 ENT consultants), four in Wales (four ENT consultants) and two in Scotland (one ENT consultant).
Five ENT consultants reported using other interventional procedures: three reported use of intralesional injections of cidofovir, one used monopolar diathermy, and one stated endoscopy without intervention.
An additional thirteen ENT consultants conducted other procedures in their recurrent respiratory papillomatosis patients prior to August 2014; these were specified via free text as: cidofovir, HPV vaccine unspecified and antireflux therapy reported by two ENT consultants, and topical mitomycin C, topical agents unspecified, vaccination, balloon dilatation, KTP laser, CO 2 laser, referral for laser, and endoscopic keel for acquired Web each reported by one ENT consultant.
The estimates of the number of recurrent respiratory papillomatosis patients and the number of Coblation treatments conducted in these patients identified from Hospital Episode Statistics are described in Table 4 .
Discussion
Synopsis of key/new findings
The results of this study represent the largest and most complete response to a nationwide survey of recurrent respiratory papillomatosis in the UK. The high response rate achieved with this survey would not have been possible without the full support of ENT UK and the Chief Medical Officers of the devolved nations. The reason for the survey was to inform future national guidance, through National Institute for Health and Care Excellence, for interventional procedures for recurrent respiratory papillomatosis and to *Survey not disseminated further due to lack of ENT consultants in organisation. Table 3 . Total number of ENT consultants conducting specified types of recurrent respiratory papillomatosis intervention and the total number of times they were conducted in the last 12 months (August 2014-July 2015)
Total no. of ENT consultants using procedure (%) assess the potential future benefits of investment in a procedure register. Our study identified a population of 918 patients with recurrent respiratory papillomatosis currently being managed in the UK acute hospital sector. This recurrent respiratory papillomatosis population size is comparable with previous studies conducted in other countries. Estimated recurrent respiratory papillomatosis rates in the United States are between 1 and 4 per 100 000 of the general population, 9 which, when extrapolated to the general population size of the UK, provides an estimate of between 646 and 2584 people with recurrent respiratory papillomatosis in the UK. Although the estimated recurrent respiratory papillomatosis population of 918 is at the lower end of the range predicted by applying the US rates to UK population size, it is still within the same order of magnitude and as such, it is an entirely plausible result. This survey will provide a baseline estimate of prevalence for further epidemiological studies in the future, for example the effect of the National HPV vaccination program in the UK in recurrent respiratory papillomatosis. Genital warts, like recurrent respiratory papillomatosis, are caused by HPV6/ 11. With the introduction of HPV vaccination in Australia, genital warts have reduced significantly. 10 To encourage completion of the survey, particular attention was given to making the survey focussed and concise. To avoid additional burden upon respondents, a decision was made to conduct a survey of prevalence, and as such, we did not attempt to quantify incidence of newly diagnosed patients in the preceding 12 months.
The number of Coblation procedures conducted in England, as obtained by the national survey, is in broad agreement with the results from Hospital Episode Statistics inpatient data. This may be explained by the availability of the specific supplementary Office of Population Censuses and Surveys Classification of Interventions and Procedures code Y10.1 which indicates 'Coblation'.
Strengths of the study
One hundred and eighty-two individual NHS healthcare trusts and health boards in the UK were approached with the national recurrent respiratory papillomatosis survey, and approximately of these 86% responded. General use of inpatient administrative data to determine epidemiology of any disease is likely to provide a lower estimate; however, we were able to validate estimates of recurrent respiratory papillomatosis and frequency of use of Coblation obtained from our survey using Hospital Episode Statistics inpatient data due to high admission/intervention rate associated with the recurrent respiratory papillomatosis condition.
Limitations of the study
In administering the online survey, responses were received from 86% of organisations but only 45% of ENT consultants in the UK. From ENT UK membership numbers, it is likely that some consultants did not respond because they had no recurrent respiratory papillomatosis patients under their care. The total number of recurrent respiratory papillomatosis patients identified from our national online survey should not be scaled up to provide a representative figure of prevalence from the entire UK. Instead, the total number of 918 recurrent respiratory papillomatosis patients should be considered as a lower estimate of the number patients managed with the disease in the UK.
In analysing Hospital Episode Statistics data, we acknowledge that 'D10' and 'D14' subchapters of ICD10 ('Benign neoplasm of mouth & pharynx' and 'Benign neoplasm of middle ear & respiratory system') are used for other conditions such as polyps in the airway, as well as recurrent respiratory papillomatosis. Some clinical coders appear to include the additional ICD-10 code B97.7 ['Papillomavirus as cause of disease (NEC)'] to specify recurrent respiratory papillomatosis patients more clearly; however, this approach is not widely adopted across the NHS. In an attempt to restrict our Hospital Episode Statistics analysis to likely recurrent respiratory papillomatosis patients, we defined recurrent respiratory papillomatosis patients as those with multiple hospital admissions during a given year. This approach was likely to remove the majority of patients with non-recurrent respiratory papillomatosis diagnoses, however, and would also exclude true recurrent respiratory papillomatosis patients with a single hospital admission -this trade-off was considered acceptable. In terms of clinical coding of procedures, the Office of Population Censuses and Surveys Classification of Interventions and Procedures code for Coblation (supplementary code for method of approach, Y10.1 'Coblation') is specific to the intervention. However, as Coblation can be also used during polypectomy (removal of polyps from airway), its use does not make the searches of administrative data specific to recurrent respiratory papillomatosis. Results obtained from Hospital Episode Statistics are also limited by potential missing data where none of the specified diagnosis or procedure codes were used.
Conclusion
Within the limitations of the survey, a lower estimate of the prevalence of recurrent respiratory papillomatosis patients currently requiring management in the secondary and tertiary health sector appears to be in the order of 1.42 per 100 000 UK population. This is in line with previous studies conducted in other countries. Our survey completed by 86% of NHS healthcare trusts and health boards estimated 918 patients with recurrent respiratory papillomatosis were managed in the UK acute hospital sector in the last year.
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Keypoints
• A total of 150 ENT consultants reported managing 918 patients with recurrent respiratory papillomatosis. 133 reported no patients with recurrent respiratory papillomatosis. This might imply that some departments have adopted a strategy to allow designated consultants to take the majority of cases hence allow an expertise to develop for this relatively rare condition.
• ENT surgeons who manage patients with recurrent respiratory papillomatosis conducted a median of 4 procedures per annum.
• Microdebrider was the most common treatment used.
• Only 3.3% of procedures for recurrent respiratory papillomatosis used radiofrequency cold ablation (Coblation).
• The use of adjuvant medical therapy reported was minimal.
• Recurrent respiratory papillomatosis prevalence appears to be near 1.42/100 000 UK population.
